AU2016226098B2 - Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity - Google Patents

Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity Download PDF

Info

Publication number
AU2016226098B2
AU2016226098B2 AU2016226098A AU2016226098A AU2016226098B2 AU 2016226098 B2 AU2016226098 B2 AU 2016226098B2 AU 2016226098 A AU2016226098 A AU 2016226098A AU 2016226098 A AU2016226098 A AU 2016226098A AU 2016226098 B2 AU2016226098 B2 AU 2016226098B2
Authority
AU
Australia
Prior art keywords
ser
val
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016226098A
Other languages
English (en)
Other versions
AU2016226098A1 (en
Inventor
Julie BIRD
Huawei Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2016226098A1 publication Critical patent/AU2016226098A1/en
Application granted granted Critical
Publication of AU2016226098B2 publication Critical patent/AU2016226098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016226098A 2015-03-04 2016-03-03 Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity Active AU2016226098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128149P 2015-03-04 2015-03-04
US62/128,149 2015-03-04
PCT/US2016/020780 WO2016141245A1 (en) 2015-03-04 2016-03-03 Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity

Publications (2)

Publication Number Publication Date
AU2016226098A1 AU2016226098A1 (en) 2017-10-26
AU2016226098B2 true AU2016226098B2 (en) 2021-11-25

Family

ID=55524479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016226098A Active AU2016226098B2 (en) 2015-03-04 2016-03-03 Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity

Country Status (22)

Country Link
US (4) US11325970B2 (enExample)
EP (3) EP4495137A3 (enExample)
JP (1) JP6745275B2 (enExample)
KR (3) KR102560072B1 (enExample)
CN (1) CN107787329B (enExample)
AR (1) AR103840A1 (enExample)
AU (1) AU2016226098B2 (enExample)
DK (1) DK3265487T3 (enExample)
ES (2) ES2994790T3 (enExample)
HR (1) HRP20221142T1 (enExample)
HU (1) HUE059644T2 (enExample)
IL (1) IL254239B2 (enExample)
LT (1) LT3265487T (enExample)
MX (1) MX382703B (enExample)
PL (1) PL3265487T3 (enExample)
PT (1) PT3265487T (enExample)
RS (1) RS63589B1 (enExample)
RU (1) RU2728858C2 (enExample)
SG (2) SG10201908019UA (enExample)
SI (1) SI3265487T1 (enExample)
TW (1) TWI733661B (enExample)
WO (1) WO2016141245A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
CN112313333A (zh) * 2018-05-10 2021-02-02 秘来生物制剂株式会社 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
JP7870729B2 (ja) * 2020-03-31 2026-06-05 メディミューン，エルエルシー 安定化ＩｇＧ４抗体及びその使用
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
KR20230038701A (ko) * 2020-06-12 2023-03-21 브리스톨-마이어스 스큅 티지에프 베타 인크. 형질전환 성장 인자 베타(TGFβ) 결합제 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
EP1486560A3 (en) 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN101084007A (zh) * 2004-09-22 2007-12-05 金齐姆公司 TGF－β拮抗剂限制免疫抑制剂肾毒性的用途
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
CA2632799A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
CN101553254A (zh) 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
JP6495884B2 (ja) 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗ｔｇｆベータ抗体および抗原結合フラグメント
AU2014235933B2 (en) * 2013-03-20 2019-01-24 Baylor College Of Medicine Methods for treating osteogenesis imperfecta
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Also Published As

Publication number Publication date
JP6745275B2 (ja) 2020-08-26
EP4495137A2 (en) 2025-01-22
US20250179163A1 (en) 2025-06-05
EP4163299B1 (en) 2024-10-02
DK3265487T3 (da) 2022-09-26
EP3265487B1 (en) 2022-06-29
PT3265487T (pt) 2022-09-29
AU2016226098A1 (en) 2017-10-26
EP3265487A1 (en) 2018-01-10
ES2927297T3 (es) 2022-11-04
TWI733661B (zh) 2021-07-21
BR112017018678A2 (pt) 2018-04-17
ES2994790T3 (en) 2025-01-31
KR20230116946A (ko) 2023-08-04
TW201706306A (zh) 2017-02-16
AR103840A1 (es) 2017-06-07
LT3265487T (lt) 2022-09-26
KR102560072B1 (ko) 2023-07-25
CA2978439A1 (en) 2016-09-09
RU2728858C2 (ru) 2020-07-31
RS63589B1 (sr) 2022-10-31
EP4495137A3 (en) 2025-03-26
MX2017011252A (es) 2018-02-19
US20180044412A1 (en) 2018-02-15
PL3265487T3 (pl) 2023-01-23
CN107787329B (zh) 2021-08-24
SI3265487T1 (sl) 2022-10-28
KR20170120689A (ko) 2017-10-31
RU2017134043A (ru) 2019-04-05
HUE059644T2 (hu) 2022-12-28
JP2018512124A (ja) 2018-05-17
KR20240076851A (ko) 2024-05-30
WO2016141245A1 (en) 2016-09-09
US11834495B2 (en) 2023-12-05
IL254239A0 (en) 2017-10-31
US20220315649A1 (en) 2022-10-06
RU2017134043A3 (enExample) 2019-08-29
MX382703B (es) 2025-03-13
HRP20221142T1 (hr) 2022-11-25
SG10201908019UA (en) 2019-10-30
US11325970B2 (en) 2022-05-10
IL254239B2 (en) 2023-06-01
US20240117028A1 (en) 2024-04-11
CN107787329A (zh) 2018-03-09
KR102668864B1 (ko) 2024-05-27
EP4163299A1 (en) 2023-04-12
EP4163299C0 (en) 2024-10-02
SG11201707109XA (en) 2017-09-28
US12162933B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
US12162933B2 (en) Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
US12473356B2 (en) scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
CA2978439C (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40119111A (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40091838A (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK40091838B (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
CA2978459C (en) Scfv-fc dimers that bind transforming growth factor-.beta.1 with high affinity, avidity and specificity
HK40117203A (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK1249113A1 (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
HK1249113B (en) Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)